EVOLUTION AT MERCK - INVENTING FOR LIFE

KEYTRUDA: EARLY EVIDENCE IN BREAST CANCER; 10 ONGOING TRIALS 100 90 80 70 Pathological Complete Response (%) 60 50 40 30 10 10 50 60 80 80 80 80 60 60 20 30 50 50 20 20 урто урно ypTO/Tis ypNO N = 60 K KEYTRUDA Np = Nab-pac A = doxorubicin C cyclophosphamide Cb carboplatin T = paclitaxel Cohort A: KNp/KAC Cohort B: KNpCb/ KAC Reg 1 Cohort C: KNpCb/ KAC Reg 2 Cohort D: KNpCb/ KAC Reg 3 Cohort E: KTCb / KAC Reg 1 Cohort F: KTCb / KAC Reg 2 Encouraging results from KEYNOTE-173 show promise in adjuvant / neoadjuvant settings MERCK # Dr. Roy Baynes H INVENTING FOR LIFE 53

View entire presentation